Citation: M. Buysschaert et Mp. Hermans, Hyperhomocysteinemia and macroangiopathy in type 2 diabetes - Response, DIABET CARE, 24(6), 2001, pp. 1124-1125
Citation: S. Deckers et al., Therapy, glycaemic control and complications in type 1 diabetic patients: Results from a single centre cohort of 465 subjects, ACT CLIN B, 56(5), 2001, pp. 289-296
Authors:
Buysschaert, M
Wallemacq, PE
Dramais, AS
Hermans, MP
Citation: M. Buysschaert et al., Hyperhomocysteinemia in type 2 diabetes - Relationship to macroangiopathy,nephropathy, and insulin resistance, DIABET CARE, 23(12), 2000, pp. 1816-1822
Citation: Mp. Hermans et al., Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes, DIABETOLOG, 42(6), 1999, pp. 678-687
Citation: Mp. Hermans et al., Comparison of tests of B-cell function across a range of glucose tolerancefrom normal to diabetes, DIABETES, 48(9), 1999, pp. 1779-1786
Citation: M. Buysschaert et Mp. Hermans, Glycaemic and blood pressure controls achieved in a cohort of 318 patientswith type 2 diabetes, ACT CLIN B, 54(6), 1999, pp. 328-333
Citation: Mp. Hermans et al., Insulin lispro (Humalog((R))), a novel fast-acting insulin analogue for the treatment of diabetes mellitus: Overview of pharmacological and clinical data, ACT CLIN B, 54(5), 1999, pp. 233-240
Authors:
Bex, M
Buysschaert, M
De Leeuw, I
De Schepper, J
Fery, F
Hermans, MP
Keymeulen, B
Lauvaux, JP
Letiexhe, M
Mathieu, C
Nobels, FR
Rottiers, R
Scheen, A
Schmitt, H
Van Crombrugge, P
Van Gaal, L
Citation: M. Bex et al., Insulin lispro (Humalog((R))) in the treatment of diabetes mellitus: Overview of Belgian clinical data from global studies, ACT CLIN B, 54(5), 1999, pp. 241-245
Citation: Fr. Nobels et al., Insulin lispro (Humalog((R))), a novel fast-acting insulin analogue: Guidelines for its practical use, ACT CLIN B, 54(5), 1999, pp. 246-254